Is Boston Scientific (BSX) a risky stock?
As of July 21, 2026, Clavix grades Boston Scientific (BSX) C+ for risk, a composite score of 62 out of 100 on an A+ to F scale, which puts BSX in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind BSX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BSX scores on each, as of July 21, 2026.
What's moving BSX's risk right now
Company-specific signals Clavix flags behind BSX's current grade, drawn from recent news and filings as of July 21, 2026.
Shares fell after weak Q1 results, but Boston Scientific's underlying business posted 15.7% organic revenue growth and 9.1 percentage points of FCF margin expansion. The gap between quarterly disappointment and business strength is the key debate.
Allspring Global Investments sold nearly half of its Boston Scientific holdings during the first quarter, per its SEC filing. Large institutional cuts can add selling pressure on a stock.
What a C+ grade means
On the Clavix A+ to F scale, BSX's composite of 62 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BSX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.